Statistically Significant Final 2-Yr OS Data from Ph 2b Trial of OST-HER2 in the Prevention or Delay of Recurrent Pulmonary Metastatic Osteosarcoma Announced
“The continued outperformance in overall survival of OST-HER2 when compared with historical control is exactly what we were hoping for when we started the Company in 2018,” said Paul Romness, MPH, Chairman & CEO of OS Therapies. “We have had highly productive regulatory meetings with the United Kingdom’s (UK) Medicines and Healthcare products Regulatory Agency (MHRA), the United States (US) Food & Drug Administration (FDA) and the European Medicines Agency’s (EMA) Dutch rapporteur. Representatives of all three regulatory agencies, in various ways, indicated that overall survival may be an appropriate clinical endpoint to support a conditional marketing authorization, especially when supported with biomarker data. The rationale for overall survival combined with biomarkers is largely a result of the compelling data recently published in canine osteosarcoma by researchers at the University of Pennsylvania.”
Share:
More News
“Our goal is not simply to complete a Phase 1 trial; it is to deliver a re-sensitization solution that changes the post-progression treatment paradigm and positions Kairos as the essential complement to the EGFR-targeted therapy market with this clean safety profile now confirmed across 13 patients,” said Dr. John Yu,
Dr. Michael GE, CEO of Kelun-Biotech, stated: “We are delighted to see that sac-TMT combined with pembrolizumab has achieved exciting positive results compared with immunotherapy plus chemotherapy in the first-line treatment of patients with PD-L1-negative NSCLC. This ADC plus immunotherapy regimen has previously demonstrated superior efficacy over immunotherapy monotherapy in
“This Fast Track designation represents another important regulatory milestone for Oncolytics and reflects the significant progress we have made over the past twelve months in advancing pelareorep toward potential registration,” said Jared Kelly, Chief Executive Officer of Oncolytics. “During that time, we have received Fast Track designation in both metastatic
“These findings build upon the well-established role of KEYTRUDA in endometrial cancer, one of the few cancers with rising incidence rates,” said Dr. Gursel Aktan, vice president, global clinical development, Merck Research Laboratories. “We are committed to helping women facing this disease by advancing potential treatment options. We thank the